Skip to content
Sign In

Main Navigation

James Sharp Logo
  • Individuals
    Individuals

    Choose Your Level of Service

    • Discretionary ServiceDiscretionary Service
    • Execution Only ServiceExecution Only Service
  • Charities & Trustees
    Charities & Trustees

    Choose Your Level of Service

    • Discretionary ServiceDiscretionary Service
    • Execution Only ServiceExecution Only Service

  • Companies
    Companies

    Choose Your Level of Service

    • Discretionary ServiceDiscretionary Service
    • Execution Only ServiceExecution Only Service

  • News & Insights
    • News & Insights
    • Current Research Coverage List
  • About Us
    • About Us
    • Our People
  • Conectus Portal
  • Contact Us

Market News - Page 588

21 January 2020

BHP Group Plc – Operational Review Half Year Ended 31 Dec 2019

BHP Group issue operation review for the half-year ended 31 December 2019…

20 January 2020

Intu Properties Plc – Market Update

Further to recent press speculation, intu properties plc (“intu” or the “Company”) continues to make progress in its strategy to fix the balance sheet….

20 January 2020

AstraZeneca Plc – FDA grants Lynparza Priority Review for PROfound

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that a supplemental New Drug Application for Lynparza (olaparib) has been accepted and granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, who have progressed following prior treatment with a new hormonal agent….

20 January 2020

AstraZeneca Plc – Imfinzi, tremelimumab granted ODD in liver cancer

AstraZeneca's Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer.

…

20 January 2020

Fevertree Plc – Year End Trading Update

Fever-Tree, the world's leading supplier of premium carbonated mixers, announces its trading update for the year ended 31st December 2019, ahead of reporting its Preliminary Results on 24th March 2020….

20 January 2020

Accrol Group Holdings – Regulatory investigation closed

Further to Accrol's announcements dated 21 January 2019 (RNS number 6698N) and 27 March 2019 (RNS number 1694U) notifying the market of an FCA investigation into the Company, Accrol is pleased to announce that the FCA has notified it that the FCA has closed its investigation and will not be taking any action…

20 January 2020

Sequoia Econ Infrastructure Income Fund Limited

SEQI, the specialist investor in economic infrastructure debt, is pleased to announce that the Company has materially deployed or committed the proceeds of its £280 million Revolving Credit Facility (the “RCF”). As at 31 December 2019, the Company had outstanding drawings on its RCF of £224 million and cash of £55.8 million, resulting in net leverage of £168.2 million. In addition, the Company had undrawn commitments on existing investments collectively valued at £92.7 million….

20 January 2020

Henry Boot Plc – Trading Update ended 31st December

The Board of Henry Boot PLC issues the following trading update for the year ended 31 December 2019 ahead of the preliminary statement of results which will be issued on 31 March 2020….

Posts navigation

  • «
  • 1
  • …
  • 586
  • 587
  • 588
  • 589
  • 590
  • …
  • 904
  • »

Home > Market News > Page 588

James Sharp white Logo
Sign In
Linkedin Icon

The Exchange
5 Bank Street
Bury, Lancashire
BL9 0DN

Tel: 0161 764 4043

Fax: 0161 764 1628

Email: mail@jamessharp.co.uk

Linkedin Icon

James Sharp & Co is a trading name
of James Sharp & Co LLP (0C422665)

Members of the LLP are referred to as Partners

  • Downloads & Resources
  • Complaints
  • Financial Compensation Scheme
  • Conectus Portal

  • Cyber Essentials Certification
  • Website Terms & Conditions
  • Privacy Policy
  • Cookie policy
  • Consent Preferences

Email Newsletter Sign-up

Consent(Required)
What we do with you information. Find out more

© Copyright 2010-2026. All rights reserved. James Sharp & Co. Authorised & Regulated by the Financial Conduct Authority
Member of the London Stock Exchange - Member of the Aquis Stock Exchange - Member of PIMFA

Website by ICG